ロード中...
Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
BACKGROUND: Spinal muscular atrophy (SMA) is a genetic disease characterized by degeneration of the spinal cord, resulting in progressive muscle atrophy. Recently, nusinersen has been approved for treating SMA, which should be administered intrathecally. CASE PRESENTATION: Patient 1 was a 36-year-ol...
保存先:
| 出版年: | JA Clin Rep |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7171013/ https://ncbi.nlm.nih.gov/pubmed/32314319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40981-020-00334-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|